FIGO Stage IVB Ovarian Cancer
This is FIGO Stage IVB ovarian cancer due to the presence of inguinal lymph node metastases, which are classified as extra-abdominal (distant) metastases. 1
Staging Rationale
The staging determination follows a clear hierarchy based on the anatomic location of lymph node involvement:
Inguinal Lymph Nodes = Stage IVB
- Inguinal lymph node metastases represent extra-abdominal disease and are definitively classified as Stage IVB 1
- This classification holds regardless of other disease sites present
- Inguinal nodes are considered distant metastases, similar to parenchymal organ metastases
Mesenteric Lymph Nodes = Stage IIIC
- Mesenteric lymph nodes are intraperitoneal nodes
- According to FIGO guidance, involvement of intraperitoneal nodes (mesentery, omentum) should be regarded as intra-abdominal disease, classified as Stage IIIC 1
- However, isolated mesenteric nodal metastases would be very unusual
Ureteral Involvement
- The question mentions "ureteral" involvement but doesn't specify the nature (direct invasion vs. obstruction)
- If this represents direct tumor extension within the pelvis/abdomen, it would contribute to Stage III disease
- However, this becomes irrelevant given the presence of inguinal node metastases
Key Staging Principle
The highest stage determines the final classification. Since inguinal lymph node involvement represents Stage IVB disease, this supersedes any Stage III findings (mesenteric nodes, ureteral involvement).
FIGO 2014 Stage IV Subdivisions 2, 3, 4:
- Stage IVA: Malignant pleural effusion (cytologically or histologically confirmed)
- Stage IVB: Parenchymal metastases and/or extra-abdominal metastases including:
- Inguinal lymph nodes
- Mediastinal lymph nodes
- Cardiophrenic lymph nodes
- Umbilical metastases
- Transmural bowel infiltration with mucosal involvement
Clinical Implications
This staging has critical prognostic significance. Patients with distant metastases (Stage IVB) have substantially worse outcomes, with 5-year relative survival rates of approximately 27% compared to 72% for regional disease 1. This patient would typically be managed with:
- Neoadjuvant chemotherapy followed by interval cytoreductive surgery, OR
- Primary cytoreductive surgery if complete resection appears feasible
- Platinum-based combination chemotherapy remains the backbone of treatment
Important caveat: Final FIGO staging should be assigned at multidisciplinary tumor board when all radiological and pathological findings are available 1. CT imaging has limitations in detecting all metastatic sites, with relatively low sensitivity (particularly for mesenteric disease at 31%) despite high specificity 5.